Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095

Clinical Infectious Diseases

Volumn 50, Issue 5, 2010, Pages 787-791

  Schouten, Jeffrey T ^a   Krambrink, Amy ^b   Ribaudo, Heather J ^b   Kmack, Anne ^e   Webb, Nancy ^e   Shikuma, Cecilia ^g   Kuritzkes, Daniel R ^c   Gulick, Roy M ^d,f  

^a UNIVERSITY OF WASHINGTON   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e Science and Technology Research Foundation   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g UNIVERSITY OF HAWAII   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ALLERGIC REACTION; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PRIORITY JOURNAL; RASH; SKIN MANIFESTATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIVIRAL AGENTS; BENZOXAZINES; FEMALE; HUMANS; LIVER; MALE; MIDDLE AGED; NEVIRAPINE; WITHHOLDING TREATMENT;

EID: 76749112870     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/650539     Document Type: Article

References (10)

1. Mehta U, Maartens G. Is it safe to switch between efavirenz and nevirapine in the event of toxicity? Lancet Infect Dis 2007; 7:733-738.
2. Ward DJ, Curtin JM. Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatrie adverse events and improvement in lipid profiles. AIDS Patient Care STDS 2006;20(8): 542-548.
3. FDA public health advisory for nevirapine (Viramune). Last updated 30 April 2009. http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ ucm051674.htm. Accessed 12 October 2009.
4. Ena J, Leach A, Nguyen P. Switching from suppressive protease inhibitor-based regimens to nevirapine-based regimens: a meta-analysis of randomized controlled trials. HIV Medicine 2008;9:747-756.
5. Kesselring AM, Wit FW, Sabin CA, et al. Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS 2009;23(13):1689-1699.
6. 6. Mocroft A, Staszewski S, Weber R, et al. Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts. Antivir Ther 2007;12(3):325-333. (Pubitemid 46787977)
7. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004;350:1850-1861.
8. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 2006;296:769-781.
9. Ribaudo HJ, Kuritzkes DR, Schackman BR, Acosta EP, Shikuma CM, Gulick RM. Design issues in initial HIV-treatment trials: focus on ACTG A5095. Antivir Ther 2006; 11(6):751-760.
10. Regulatory Compliance Center. Division of AIDS table for grading severity of adult adverse experiences. August 1992. http://rcc.tech-res.com/Document/ safetyandpharmacovigilance/ToxicityTables-Adult-TRP-v01a.pdf. Accessed 14 October 2009.